EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Ola Landgren, Thomas J. Prior, Tara Masterson, Christoph Heuck, Orlando F. Bueno, Ajeeta B. Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A. Ross, Mihaela Talpes, Jay R. Hydren, Jennifer M. Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M. Devlin

Open source

DOI: 10.1182/blood.2024024371
Published: 2024-07-25
Container: Blood
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2024024371,
  title = {EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma},
  author = {Ola Landgren and Thomas J. Prior and Tara Masterson and Christoph Heuck and Orlando F. Bueno and Ajeeta B. Dash and Hermann Einsele and Hartmut Goldschmidt and Stefan Knop and Cong Li and Ulf-Henrik Mellqvist and Ian McFadden and Corina Oprea and Jeremy A. Ross and Mihaela Talpes and Jay R. Hydren and Jennifer M. Ahlstrom and Dickran Kazandjian and Niels Weinhold and Rick Zhang and Maryalice Stetler-Stevenson and Gerald Marti and Sean M. Devlin},
  year = {2024},
  journal = {Blood},
  doi = {10.1182/blood.2024024371},
  url = {https://doi.org/10.1182/blood.2024024371}
}

RIS

TY  - JOUR
TI  - EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma
AU  - Ola Landgren
AU  - Thomas J. Prior
AU  - Tara Masterson
AU  - Christoph Heuck
AU  - Orlando F. Bueno
AU  - Ajeeta B. Dash
AU  - Hermann Einsele
AU  - Hartmut Goldschmidt
AU  - Stefan Knop
AU  - Cong Li
AU  - Ulf-Henrik Mellqvist
AU  - Ian McFadden
AU  - Corina Oprea
AU  - Jeremy A. Ross
AU  - Mihaela Talpes
AU  - Jay R. Hydren
AU  - Jennifer M. Ahlstrom
AU  - Dickran Kazandjian
AU  - Niels Weinhold
AU  - Rick Zhang
AU  - Maryalice Stetler-Stevenson
AU  - Gerald Marti
AU  - Sean M. Devlin
PY  - 2024
JO  - Blood
DO  - 10.1182/blood.2024024371
UR  - https://doi.org/10.1182/blood.2024024371
ER  -

APA

Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., Mellqvist, U., McFadden, I., Oprea, C., Ross, J. A., Talpes, M., Hydren, J. R., Ahlstrom, J. M., Kazandjian, D., Weinhold, N., Zhang, R., Stetler-Stevenson, M., Marti, G., & Devlin, S. M. (2024). EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. https://doi.org/10.1182/blood.2024024371

Source records

crossref · retrieved 2026-09-25T15:24:12.580Z